Impentri First effective pharmacotherapy for ARDS to lower mortality and improve quality of life of patients.

Summary

Acute Respiratory Distress syndrome (ARDS) is a life threatening condition that affects 3 million people world-wide. With regards to the current coronavirus pandemic, ARDS is the immediate cause of death for patients suffering from this infection. 40% of the patients that suffer from the condition succumb to it and among the ones that survive, most of them face long-term physical and mental illness. The unreliable, costly, prolonged treatment options currently available are responsible for the high mortality observed in the condition. The treatments offer only relief from symptoms and manage the condition but are not curative. Exvastat is developing impentri as a reliable and effective pharmacotherapy for ARDS as it targets the cause and trigger of the mortality associated with the condition. It is an intravenous formulation of widely-used chemotherapeutic drug, Imatinib which has shown promising results in-vitro and clinical reports in ARDS like conditions. Being a repurposed drug, Impentri has the advantage of reaching human trials earlier than other drugs. With EIC funds Exvastat plans to register and successfully finish 50% of the PhaseII trials in ARDS patients. This would provide an opening for the drug to successfully finish further trials and its orphan drug status would guarantee early market entry. With Impentri Exvastat wants to lower mortality and provide better quality of life to patients suffering from ARDS

Resources Show all and search (4)

Unfold all

Fold all

More information & hyperlinks

Web resources:	https://cordis.europa.eu/project/id/959310
Start date:	01-10-2020
End date:	30-09-2022
Total budget - Public funding:	1 798 912,00 Euro - 1 259 239,00 Euro